Mueller, Dirk, Fischer, Kirsten, Kaiser, Peter, Eichhorst, Barbara, Walshe, Ronald, Reiser, Marcel, Kellermann, Lenka, Borsi, Lisa, Civello, Daniele, Mensch, Alexander, Bahlo, Jasmin, Hallek, Michael, Stock, Stephanie and Fingerle-Rowson, Guenter (2016). Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia. Leuk. Lymphoma, 57 (5). S. 1130 - 1140. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Full text not available from this repository.

Abstract

The cost-effectiveness of rituximab in combination with fludarabine/cyclophosphamide (R-FC) for the first line treatment of chronic lymphocytic leukemia (CLL) was evaluated. Based on long-term clinical data (follow-up of 5.9 years) from the CLL8-trial, a Markov-model with three health states (Free from disease progression, Progressive disease, Death) was used to evaluate the cost per quality-adjusted life-year (QALY) and cost per life years gained (LYG) of R-FC from the perspective of the German statutory health insurance (SHI). The addition of rituximab to FC chemotherapy results in a gain of 1.1 quality-adjusted life-years. The incremental cost-effectiveness ratio (ICER) of R-FC compared with FC was Euro17 979 per QALY (Euro15 773 per LYG). Results were robust in deterministic and probabilistic sensitivity analyses. From the German SHI perspective, rituximab in combination with FC chemotherapy represents good value for first-line treatment of patients with CLL and compares favorably with chemotherapy alone.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Mueller, DirkUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fischer, KirstenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kaiser, PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Eichhorst, BarbaraUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Walshe, RonaldUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Reiser, MarcelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kellermann, LenkaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Borsi, LisaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Civello, DanieleUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mensch, AlexanderUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bahlo, JasminUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hallek, MichaelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Stock, StephanieUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fingerle-Rowson, GuenterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-290232
DOI: 10.3109/10428194.2015.1070151
Journal or Publication Title: Leuk. Lymphoma
Volume: 57
Number: 5
Page Range: S. 1130 - 1140
Date: 2016
Publisher: TAYLOR & FRANCIS LTD
Place of Publication: ABINGDON
ISSN: 1029-2403
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
THERAPY; LIFE; DIAGNOSIS; LYMPHOMA; QLQ-C30; GERMANYMultiple languages
Oncology; HematologyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/29023

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item